_edited.png)
Pipeline
Transforming Proven Therapies Into Breakthrough Treatments
We are advancing hormone-based therapeutics to address age-related diseases with a more efficient path to market.
Advancing Towards Clinical Development
Our lead program is a novel hormone-based therapeutic targeting Alzheimer's disease. Supported by strong preclinical data, we are advancing toward clinical development with a de-risked regulatory strategy.
Traditional drug discovery process
Discovery
Target
validation
Lead
optimization
Precinical
development
Phase 1
clinical trial
Phase 2
clinical trial
Phase 3
clinical trial
FDA
application
Caren Pharma’s streamlined approach
FDA
application
FDA
application
Precinical
validation
Streamlined clinical program
FDA
application
Unlocking the Potential of Hormones in Disease
Hormones play a critical role in multiple age-related diseases. Our approach has the potential to extend beyond Alzheimer's into additional indications where hormonal decline is a key driver of disease pathology.
Pipeline
PROGRAM
CORRELATION
PRECLINICAL
CLINICAL PLANNING
CLINICAL PROGRAM
CP001M
Optimized Dosing Strategy
CP002F
Optimized Dosing Strategy
Alzheimer’s Disease (Female)
Targeting Cognitive Health & Disease Pathology
CP003
Optimized Dosing Strategy
Parkinson’s
CP004
Optimized Dosing Strategy
Breast Cancer
CP005
Optimized Dosing Strategy
Prostate Cancer
CP006
Optimized Dosing Strategy
Metabolic Syndrome
CP007
Optimized Dosing Strategy
COPD
CP008
Optimized Dosing Strategy
Multiple Sclerosis
CP009
Optimized Dosing Strategy
Osteoporosis
CP010
Optimized Dosing Strategy
Adult Depression
CP011
Optimized Dosing Strategy
Sleep Apnea
Alzheimer’s Disease (Male)
Targeting Cognitive Health & Disease Pathology